Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.

HER2:39.33 ng/mL (EC50)

Margetuximab is a chimeric anti-HER2 monoclonal antibody with an optimized Fc structural domain and an EC50 value of 39.33 ng/mL.Margetuximab enhances the activity of effector cells against antibody-mediated cellular cytotoxicity (ADCC) mediated by antibody-dependent cells expressing the CD16A-158F variant. [1]

In a mouse model, weekly intraperitoneal injections of 2-4 mg/kg of Margetuximab (5-6 times) demonstrated significant tumor shrinkage on days 30-37.[1] Margetuximab has been shown to increase tumor size in mice, and has been shown to increase tumor size in mice. [1]
In a study in cynomolgus monkeys, weekly intravenous injections of 15-150 mg/kg of Margetuximab (6 doses) were well tolerated and induced a mean reduction in NK cell counts by 51% and release of IL-6. A single dose of 50 mg/kg of intravenous Margetuximab demonstrated a favorable safety profile. [1]

Human

Monoclonal

Unconjugated